|
Dec 5
|
Pfizer (NYSE:PFE) shareholders have endured a 40% loss from investing in the stock a year ago
|
|
Dec 4
|
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
|
|
Dec 4
|
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
|
|
Dec 4
|
Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
|
|
Dec 4
|
ProPicks: Beat the S&P 500 with our cutting-edge AI-powered stock selection
|
|
Dec 3
|
Is Pfizer Stock a Buy Now?
|
|
Dec 2
|
Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes
|
|
Dec 2
|
An Important History Lesson for Gene-Editing Investors
|
|
Dec 2
|
5 Top Stocks to Buy Before 2024
|
|
Dec 1
|
S&P 500 Gains and Losses Today: Ulta Has a Beauty of an Earnings Report
|
|
Dec 1
|
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
|
|
Dec 1
|
US STOCKS-S&P 500 hits 2023 closing high as Powell strengthens peak rate bets
|
|
Dec 1
|
US STOCKS-Wall St rallies as Powell cements peak rate bets
|
|
Dec 1
|
Pfizer slumps after pulling obesity-drug study following patient reactions
|
|
Dec 1
|
Pfizer abandons plans for twice-daily weight-loss pill over side effects
|
|
Dec 1
|
Midday Movers: Ulta Beauty and Paramount Global Rise, Pfizer and Tesla Fall
|
|
Dec 1
|
Pfizer Shares Drop as It Ends Study of Weight-Loss Pill Due to Patient Side Effects
|
|
Dec 1
|
Why Pfizer Stock Is Sinking Today
|
|
Dec 1
|
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
|
|
Dec 1
|
Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous
|